Lilly’s Foundayo Receives Positive CHMP Opinion for Europe

What did the EMA committee recommend?

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting marketing authorization in the EU for Foundayo (orforglipron) for two indications: weight management in adults with obesity or overweight, and the treatment of type 2 diabetes in adults whose blood glucose is not adequately controlled. The European Commission makes the final approval decision and typically follows CHMP recommendations within a few weeks.

What is Foundayo and why does it matter?

Foundayo is Eli Lilly’s oral GLP-1 receptor agonist — a once-daily pill that can be taken at any time of day without food and water restrictions. That last point distinguishes it from other oral GLP-1 therapies currently on the market. The drug received FDA approval for obesity in April 2026 and launched commercially in the United States in the second quarter. Lilly has submitted orforglipron for regulatory review in approximately 40 markets globally.

What does this mean competitively?

If the European Commission approves Foundayo, it would become the second oral GLP-1 available in the EU for weight management, following Novo Nordisk’s Wegovy pill, which received European approval in July for weight management only. In the type 2 diabetes setting, Foundayo would compete with Novo’s Rybelsus brand of oral semaglutide, which has been on the European market since 2020 and has grown into a multi-billion-dollar franchise. The CHMP recommendation opens a new competitive front between Lilly and Novo Nordisk in Europe’s oral GLP-1 market, adding to their existing rivalry in injectable incretin therapies.

What did the clinical evidence show?

The weight management recommendation is based on two studies involving more than 4,740 adults with obesity or overweight. The type 2 diabetes recommendation is based on four studies involving 3,765 adults compared against placebo, dapagliflozin, and oral semaglutide.

FDA Approves Enspryng for Thyroid Eye Disease

What was approved?

The FDA approved Enspryng (satralizumab), an interleukin-6 receptor inhibitor developed by Roche, for adults with thyroid eye disease on October 16. Roche describes it as the first subcutaneous therapy for the condition — one that patients or caregivers can administer at home after training from a healthcare provider. It is Enspryng’s second indication; the drug was first approved in 2020 for neuromyelitis optica spectrum disorder.

What did the clinical trials show?

The approval rests on two identically designed Phase 3 trials, SatraGO-1 and SatraGO-2, which enrolled 258 adults across 19 countries. The primary endpoint was the proportion of patients with active, moderate-to-severe disease who achieved at least a 2 mm reduction in proptosis — eye bulging — at week 24. Results diverged: SatraGO-2 met its endpoint, with 52.9% of Enspryng-treated patients achieving a proptosis response versus 23.4% on placebo, and 60.7% showing reduced double vision versus 25.8%. SatraGO-1 did not reach statistical significance, with researchers attributing the gap to an unexpectedly high placebo response.

How does this change the treatment landscape?

Two disease-specific therapies were already approved — Tepezza and, more recently, Lumvoa — both administered by intravenous infusion. Enspryng’s subcutaneous, every-four-week maintenance dosing offers a different treatment experience, with the key benefit being reduced logistical burden rather than a demonstrated efficacy advantage over existing options. No head-to-head comparison with approved therapies was conducted.

What are the remaining unknowns?

Roche did not disclose pricing or launch timing. Long-term data beyond week 24 were not described in available sources. Separately, the FDA has granted priority review to a supplemental Enspryng application for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

AstraZeneca and insitro Partner on AI-Driven MASH and Cardiomyopathy Drug Discovery

What did AstraZeneca and insitro announce?

AstraZeneca signed a drug discovery collaboration with insitro to apply artificial intelligence to target identification and therapeutic design in metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in development and commercial milestones, plus single-digit royalties on global sales.

What is insitro’s platform?

Insitro’s Virtual Human platform combines large-scale human and cellular data with AI-enabled target identification and medicine design. The company was founded in 2018 and reports more than $750 million in capital raised, with existing collaborations with Bristol Myers Squibb, Lilly and Gilead. It has nine programs in development, including genetic regulators of liver fat and fibrosis expected to enter the clinic in early 2027.

Why MASH and cardiomyopathies?

Both conditions are characterized by disease heterogeneity — a single diagnostic label covering patients whose underlying biology differs — which has complicated treatment development. In MASH, the FDA approved its first treatment, resmetirom (Rezdiffra), in March 2024, but the condition still lacks therapeutic options for most of the estimated 6 to 8 million US patients with moderate-to-advanced liver scarring. The cardiomyopathy scope was not specified in the announcement.

What are the limitations of this deal?

No drug candidates were named in the announcement. The collaboration sits at the discovery stage, with targets identified through AI-driven analysis still requiring validation through preclinical and clinical work. The $40 million upfront represents less than 3% of the total headline value, and neither company disclosed timelines for milestone payments.

FDA Launches Rare Disease Framework Initiative

What is the Rare Disease Framework Initiative?

The FDA announced a new effort to redesign how drugs and biologics for rare diseases are developed and reviewed. The initiative, outlined in a white paper released by the agency’s Rare Disease Innovation Hub, aims to build a regulatory framework tailored to the realities of small patient populations — covering clinical development, evidence standards, manufacturing review, and the role of patient voice throughout the process.

Why is FDA doing this now?

Despite years of regulatory flexibility programs for rare diseases, only approximately 5% of rare conditions currently have an FDA-approved treatment. The agency says that gap reflects the need for a more fundamentally tailored approach rather than incremental adjustments to a framework originally designed for common diseases.

What are the specific commitments?

The initiative outlines six priority areas: greater clarity and predictability in regulatory decision-making through tailored guidance; embedding the patient voice early and at defined milestones; leveraging external expertise for customized review; building shared institutional knowledge; applying risk-based approaches to manufacturing and pre-approval inspections; and championing innovative statistical approaches in rare disease development.

What happens next?

The FDA is hosting a public meeting on October 28 at its White Oak campus, facilitated by the Reagan-Udall Foundation, to gather input from patients, disease advocates, industry, and other stakeholders. Additional sector-specific roundtables and requests for information will follow. The detailed framework development — which could include new guidance, regulatory changes, and organizational changes within FDA — will be informed by that input.

Gilead and Vir Biotechnology Enter $1.87 Billion Masked T-Cell Engager Collaboration

What are the two companies agreeing to develop?

Vir Biotechnology will discover and optimize three novel PRO-XTEN dual-masked T-cell engager development candidates for Gilead, targeting selected solid tumor-associated antigens. Gilead holds an exclusive license to develop, manufacture and commercialize the resulting therapies. Vir will receive $90 million upfront — including $65 million in cash and a $25 million equity investment at a 30% premium — and is eligible for up to $1.74 billion in additional milestones and tiered royalties.

What is the PRO-XTEN masking technology?

PRO-XTEN is designed to keep T-cell engagers inactive in circulation until they reach the tumor microenvironment, where tumor-specific proteases cleave the mask and activate the drug’s cancer-killing mechanism. That conditional activation is intended to limit systemic toxicity — one of the primary barriers to TCE use in solid tumors — while extending the drug’s half-life and potentially enabling less frequent dosing.

Why does this matter for solid tumor oncology?

T-cell engagers have proven highly effective in blood cancers but have faced significant limitations in solid tumors, where toxicity and the immunosuppressive tumor microenvironment have constrained clinical use. Vir’s PRO-XTEN approach directly targets those barriers. This is the second major PRO-XTEN collaboration — an earlier $1.7 billion deal with Astellas for a PSMA-targeted TCE in prostate cancer was announced in February 2026. Together the two deals bring total PRO-XTEN platform value to more than $3.6 billion across two top-tier pharma partners.

How does this fit Gilead’s oncology strategy?

Today’s deal is Gilead’s third major solid tumor oncology transaction in 2026, following the $5 billion Tubulis ADC acquisition in April and the $2.1 billion Ouro Medicines BCMA T-cell engager acquisition in March. Gilead is simultaneously building in ADCs, T-cell engagers for autoimmune disease, and now masked T-cell engagers for solid tumors — a deliberate multi-mechanism oncology buildout executed across a single year.

Bausch + Lomb Appoints Thomas Appio as Interim CEO

What happened at Bausch + Lomb?

Bausch + Lomb announced that Brent Saunders departed as CEO by mutual agreement, with Thomas J. Appio named interim CEO effective immediately. Appio, who will retain his role as CEO of parent company Bausch Health, steps into the position just weeks before the company reports third-quarter results and updates its full-year guidance on October 28.

What does the company expect for 2026?

Simultaneously with the leadership announcement, both Bausch + Lomb and Bausch Health said they expect to raise their full-year 2026 adjusted EBITDA guidance based on preliminary third-quarter results, citing strong business performance and anticipated momentum through year-end.

What was Saunders building?

Saunders returned to Bausch + Lomb in March 2023 — his second stint as CEO — and spent three years stabilizing the company’s supply chain, accelerating commercial execution, and rebuilding its R&D pipeline. The company had launched more than 20 new products and built a pipeline of more than 60 projects, including first-in-class candidates for glaucoma neuroprotection, a dual-action dry eye combination, and a new bioactive contact lens material. Projected peak sales for the pipeline totaled approximately $7 billion, post-2028, if programs succeed. In a December 2025 Pharmaceutical Executive profile, Saunders said he had “zero regrets” about his return and that the company’s “best few years are right in front of us.”

What are the key questions going forward?

Investors will look to the October 28 earnings call for clarity on whether the ambitious R&D roadmap Saunders built will continue under Appio’s leadership, and whether the guidance raise reflects durable business momentum or pulls forward favorable timing. No permanent CEO search timeline has been disclosed.